Talk:4F-MDMB-BINACA

Pharmacology Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Low	This article has been rated as Low-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Naming scheme

It should be mentioned that the name "4F-MDMB-BINACA" is an acronym of Methyl 2-[1-(4-FluoroButyl)-1H-INdAzole-3-CarboxAmide]-3,3-DiMethylButanoate. Enix150 (talk) 00:26, 17 January 2020 (UTC)[reply]

UK Legal Status

This is a class B drug covered by the blanket ban clause in Misuse of Drugs Act 1971 - paragraph 1(ca) of Part 2 of Schedule 2^[1]

(ca)any compound (not being a compound for the time being specified in sub-paragraph (c) above) structurally related to 1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with a benzyl or phenyl group and whether or not such compound is further substituted to any extent with alkyl, alkenyl, alkoxy, halide, haloalkyl or cyano substituents and, where any of the sub-structures have been modified, the modifications of the sub-structures are limited to any of the following, that is to say—

(i)replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-c]pyridine or pyrazolo[3,4‑b]pyridine;

(ii)replacement of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl or (tetrahydropyran-4-yl)methyl;

(iii)replacement of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene bridge or methine group;

(iv)replacement of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl, cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl, 1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1-amino-1-oxopropan-2-yl, 1‑hydroxy-1-oxopropan-2-yl, piperidinyl, morpholinyl, pyrrolidinyl, tetrahydropyranyl or piperazinyl.

4F-MDMB-BINACA is a modification of JWH-018 by the following changes:

Replacement of the indole ring with indazole
Replacement of the methanone linking group with carboxamide
Replacement of 1-napthyl with 1-hydroxy-1-oxopropan-2-yl
The 1-hydroxy-1-oxopropan-2-yl is subsequently modified by addition of methyl groups to get to methyl-dimethyl-butanoate
Replacement of pentyl with n-butyl (alkyl substitution)
Addition of fluoride to the n-butyl chain (halide substitution of alkyl chain)

Testem (talk) 21:53, 18 October 2020 (UTC)[reply]

References

^ "Misuse of drugs act". Legislation.gov. UK Government. Retrieved 18 October 2020.

[1] "Misuse of drugs act". Legislation.gov. UK Government. Retrieved 18 October 2020.

[1]